Bradley J . Monk, MD

Department

Obstetrics & Gynecology (Phoenix)

Position

Professor

Publications

• JCO precision oncology
  Coleman Robert L, Wallraven Gladice, Willoughby David, Nagel Casey, Wei Qi, Horvath Staci, Stanbery Laura, Rocconi Rodney, Monk Bradley J, Walter Adam, Rao Donald, Tang Min, Bognar Ernest, Nemunaitis John, Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer
  10:10, p. e2500462 2026
• Future oncology (London, England)
  Banerjee Susana N, Van Nieuwenhuysen Els, Aghajanian Carol, Monk Bradley J, Clamp Andrew, D'Hondt Véronique, Rodrigues Manuel, Chon Hye Sook, Holloway Robert W, Colombo Nicoletta, Gennigens Christine, Newman Gregg, Salinas Erin, Youssoufian Hagop, Santin Alessandro D, O'Malley David M, Gourley Charlie, Thaker Premal H, Van Gorp Toon, Grisham Rachel N, Lustgarten Stephanie, Prendergast Emily, Oaknin Ana, Ring Kari, Moore Kathleen N, The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201, p. 1 2025
• International journal of gynecological cancer
  Eskander Ramez N., Slomovitz Brian, Makker Vicky, Fujiwara Keiichi, Moore Kathleen N., Monk Bradley, Gonzalez-Martin Antonio, Oza Amit, Oaknin Ana, Leary Alexandra, Ali Talal, Sehouli Jalid, Rider Alex, Brown Tom, Smith Alan, Gourley Charlie, REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH ADVANCED PLATINUM-RESISTANT AND PLATINUM-SENSITIVE OVARIAN CANCER WITHIN THE UNITED STATES: AN ANALYSIS OF SECONDARY DATA
  35:11, p. 102488 2025
• International journal of gynecological cancer
  Hasegawa Kosei, Arkhipov Alexander, Yañez Eduardo, Gumus Mahmut, Hurtado De Mendoza Mivael Olivera, Samouëlian Vanessa, Castonguay Vincent, Tekin Cumhur, Toker Sarper, Monk Bradley, Li Kan, Colombo Nicoletta, Tewari Krishnansu S., Dubot Coraline, Cáceres M. Valeria, Lorusso Domenica, Shapira-Frommer Ronnie, Salman Pamela, PEMBROLIZUMAB PLUS CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN PARTICIPANTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: 5-YEAR FOLLOW-UP RESULTS FROM KEYNOTE-826
  35:11, p. 102156 2025
• International journal of gynecological cancer
  Lee Elizabeth, Yeku Oladapo, Call Justin, Winer Ira, Richardson Debra, Seamon Leigh, Hamilton Erika, Monk Bradley, Cloven Noelle, Zhang Jian, Kavalerchik Edward, PART C OF RAINFOL™-01: A PHASE 1/2 STUDY OF SINGLE-AGENT RINATABART SESUTECAN IN PATIENTS WITH ADVANCED AND/OR METASTATIC PLATINUM-RESISTANT OVARIAN CANCER
  35:11, p. 102616 2025
• International journal of gynecological cancer
  Richardson Debra, Weiner Ira, Willmott Lyndsay J., Call Justin, Pepin Jessica Thomes, Jewell Andrea, Mathews Cara, Seamon Leigh, Buscema Joseph, Monk Bradley, Guancial Elizabeth, Orr Douglas, Melnyk Anton, Gillespie Michael, Kilavuz Nurgul, Ong Teng Jin, Kavalerchik Edward, Cloven Noelle, Konecny Gottfried, Lee Elizabeth, RINATABART SESUTECAN MONOTHERAPY IN PATIENTS WITH ADVANCED ENDOMETRIAL CANCER: PART F OF THE PHASE 1/2 RAINFOL™-01 STUDY
  35:11, p. 102612 2025
• International journal of gynecological cancer
  Salani Ritu, Lee Jung-Yun, Gilbert Lucy, Sadozye Azmat H., Do Rêgo Barros Lilian Arruda, Van Gorp Toon, Boere Ingrid, Duska Linda, Marth Christian, Mądry Radosław, Zagouri Flora, Monk Bradley, Li Xin Tong, Bogusz Agata M., Toker Sarper, Lindemann Kristina, Cáceres M. Valeria, Harter Philipp, Zhongqiu Lin, Valabrega Giorgio, Nishio Shin, Oaknin Ana, Kurtz Jean-Emmanuel, Canova Stefania, TROFUSE-020/GOG-3101/ENGOT-CX20: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL, MULTICENTER STUDY COMPARING SACITUZUMAB TIRUMOTECAN MONOTHERAPY VS TREATMENT OF PHYSICIAN’S CHOICE AS SECOND-LINE TREATMENT FOR RECURRENT/METASTATIC CERVICAL CANCER
  35:11, p. 102609 2025
• International journal of gynecological cancer
  Secord Angeles Alvarez, Sill Michael, Lankes Heather, Newton Meredith, Leitao Mario, Ramondetta Lois, Clair Kiran, Guntupalli Saketh, Iii Charles Leath, Richardson Debra, Disilvestro Paul, Cantuaria Guillerme, Billingsley Caroline, Mcdonald Megan, Liu Yingmiao, Starr Mark, Birrer Michael, Monk Bradley, Brady Chris, Lea Jayanthi, Ueland Frederick, Chambers Laura, Tewari Krishnansu S., Nixon Andrew, PREDICTIVE BLOOD-BASED BIOMARKERS IN CERVICAL CANCER PATIENTS TREATED WITH PACLITAXEL-BASED CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: RESULTS FROM GOG-0240
  35:11, p. 102158 2025
• International journal of gynecological cancer
  Nicum Shibani, Marth Christian, Wang Jian Liu, Lu Chien-Hsing, Monk Bradley, Freitas-Junior Ruffo, Zagouri Flora, Segev Yakir, Collins Dearbhaile C., Kümmel Jan, Petrella Maria Cristina, Lassus Heini J., Fujiwara Keiichi, Jaishuen Atthapon, Cáceres M. Valeria, Crafton Sarah, Kruger Stephan, Black Destin, Slomovitz Brian M., Orlowski Robert, Yao Lili, GOG-3119/ENGOT-EN29/TROFUSE-033: A PHASE 3, RANDOMIZED STUDY OF SACITUZUMAB TIRUMOTECAN PLUS PEMBROLIZUMAB VS PEMBROLIZUMAB ALONE AS FIRST-LINE MAINTENANCE THERAPY FOR MISMATCH REPAIR-PROFICIENT ENDOMETRIAL CANCER
  35:11, p. 102611 2025
• International journal of gynecological cancer
  Vergote Ignace, Perez Fidalgo Jose Alejandro, Valabrega Giorgio, Colombo Nicoletta, Monk Bradley, Herzog Thomas, Cibula David, Pothuri Bhavana, Sehouli Jalid, Korach Jakob, Richardson Debra, Barlin Joyce, Papadimitriou Christos, Van Gorp Toon, Mccarthy Michael, Antill Yoland, Li Kai, Kalyanapu Pratheek, Slomovitz Brian, Coleman Robert, ENGOT-EN20/GOG-3083/XPORT-EC-042 A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA
  35:11, p. 102472 2025
• International journal of gynecological cancer
  Lorusso Domenica, Monk Bradley, Martin Lainie, Schenker Michael, Maximiano Constanza, Barlin Joyce, Kim Yong Man, Bese Tugan, Rose Peter G., Chang Chih-Long, Pospiskova Marketa, Salinas Erin A., Malander Susanne, Santin Alessandro D., Collins Dearbhaile C., Willmott Lyndsay, Craib Marcia, Chui Joshua, Fujiwara Keiichi, Kristeleit Rebecca, SAFETY OF RUCAPARIB MONOTHERAPY IN ADVANCED HIGH-GRADE OVARIAN CANCER CLINICAL TRIALS
  35:11, p. 102262 2025
• Gynecologic oncology
  Chase Dana M, Cho Chi Heum, Kim Jae-Weon, No Jae Hong, Smick Alexandra H, Holman Laura, Stuckey Ashley, Fabian Denise, Wenzel Lari, Gil Karen, Ryu Sang Young, Mayadev Jyoti, Huang Helen Q, Deng Wei, Koh Wui-Jin, Rodgers William, Small, Jr William, Albuquerque Kevin, Leath Charles A, Kim Dae-Yeon, Monk Bradley, Kim Beob-Jong, Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263)
  202, p. 102 - 109 2025
• Journal of clinical oncology
  Monk Bradley J, Coleman Robert L, O'Malley David M, Moore Kathleen N, González-Martín Antonio, Herzog Thomas J, Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer, p. JCO2501721 2025
• Molecular cancer therapeutics
  Leary Alexandra, Frenel Jean-Sébastien, Willmott Lyndsay, Monk Bradley J., Starks David C., Okera Meena, Secord Angeles Alvarez, O’Malley David M., Martin Lainie, Ouali Kaissa, Lim Peter C., Oehler Martin K., Goh Jeffrey C., Slomovitz Brian M., Shannon Catherine M., Chung Heekyung, Neff Robert, Backes Floor J., Rajendran Divya, Kim Doris, Li Hailun, Jandial Danielle, Simpkins Fiona, Abstract B013: Cyclin E1 Positive Protein Status is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer: Part 2 of the DENALI Study (GOG-3066)
  24:10_Supplement, p. B013 - B013 2025
• Annals of oncology
  Kristeleit R S, Maloney L, Drochytek V, Eskander R N, Agarwal R, Despain D, Fujiwara K, Connor C, Craib M, Shih D, Monk B J, Fuentes Pradera J, Ghamande S, Lisyanskaya A, Oaknin A, Prendergast E, Kim Y B, Littell R D, Dean A, Gao B, Valabrega G, O'Malley D M, Zagouri F, Pisano C, Buscema J, Provencher D, Ueland F, Martin L P, Chou H-H, Demirkiran F, Anderson C, Chudecka-Głaz A, Yeku O, Beiner M, Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study 2025
• Journal of clinical oncology
  Banerjee Susana N, D'Hondt Véronique, Van Nieuwenhuysen Els, Aghajanian Carol, Monk Bradley J, Clamp Andrew, Prendergast Emily, Holloway Robert W, Oaknin Ana, Ring Kari, Colombo Nicoletta, Rodrigues Manuel, Chon Hye Sook, Gennigens Christine, Gourley Charlie, Santin Alessandro D, Thaker Premal H, Newman Gregg, Salinas Erin, Youssoufian Hagop, Moore Kathleen N, Lustgarten Stephanie, O'Malley David M, Van Gorp Toon, Grisham Rachel N, Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201, p. JCO2502377 2025
• Obstetrical & gynecological survey
  Olawaiye Alexander B., Vergote Ignace, Kesner-Hays Amanda, Pashova Hristina I., Pai Sachin G., Tudor Iulia Cristina, Jubb Adrian M., Lorusso Domenica, O'Malley David M., Kim Jae-Weon, Garbaos Gabriel, Salutari Vanda, Artioli Grazia, Caruso Giuseppe, Nicum Shibani, Bagameri Andrea, Bodnar Lubomir, Kim Byoung-Gie, Colombo Nicoletta, De La Creva Helena, McClung Emily, Kaczmarek Emilie, Slomovitz Brian, do Carvalho Calabrich Aknar Freire, Cassani Chiara, You Benoit, Churruca Cristina, Hopp Elizabeth, Gilbert Lucy, Mileshkin Linda, Devaux Alix, Lee Yong Jae, Oaknin Ana, Scaranti Mariana, Leiser Aliza L., McCollum Michael E., Diakos Connie, Clamp Andrew, Balazs Boglárka, Monk Bradley J., Scandurra Giuseppa, Van Gorp Toon, Kang Sokbom, Gladieff Laurence, Relacorilant and Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer (ROSELLA): An Open-label, Randomized, Controlled, Phase 3 Trial
  80:10, p. 636 - 638 2025
• Annals of oncology
  Ryu S Y, Leath, 3rd C A, Gil K M, Small, Jr W, Rodgers W, Deng W, Albuquerque K, Koh W-J, Fabian D, Chase D M, Miller K, No J H, Mannel R S, Cho C-H, Monk B J, Mayadev J, Heugel A, Kim J-W, Kim B-J, Kim D-Y, Randomized Phase III Trial of Adjuvant Radiation versus Chemoradiation in Intermediate-Risk, Early-stage Cervical Cancer following Radical Hysterectomy and Lymphadenectomy: Results from NRG Oncology/GOG-263/KGOG1008 2025
• Konstantinopoulos Panagiotis A, Kim Jae Weon, Freyer Gilles, Colombo Nicoletta, Lee Jung Yun, Gaba Lydia, Grisham Rachel N, Wu Xiaohua, Sehouli Jalid, Cruz Felipe, Friedlander Michael, Cibula David, Monk Bradley J, Nyvang Gitte Bettina, Lorusso Domenica, Van Nieuwenhuysen Els, Malik Rozita, Cortés-Salgado Alfonso, Glasspool Rosalind, Marth Christian, Leary Alexandra, Zamagni Claudio, Marmé Frederik, Sufliarsky Jozef, Su Fei, Zuradelli Monica, Wang Craig, Hinson Patsy, Paule Ines, Miller Michelle, Matulonis Ursula A, González-Martín Antonio, Primary Analysis of EPIK-O/ENGOT-ov61:Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation 2025
• Gynecologic oncology
  Levin Gabriel, Pothuri Bhavana, Monk Bradley, Coleman Robert, Herzog Thomas, Slomovitz Brian, Racial and ethnic enrollment disparities in clinical trials leading to drug approvals for gynecologic malignancies by the Food and Drug Administration
  200, p. 150 2025
• Gynecologic oncology
  Lee Elizabeth, Call Justin, Winer Ira, Hamilton Erika, Yeku Oladapo, Richardson Debra, Seamon Leigh, Cloven Noelle, Zhang Jian, Kavalerchik Edward, Monk Bradley, Part C of a phase I/II study evaluating single agent rinatabart sesutecan in patients with advanced and/or metastatic platinum-resistant ovarian cancer
  200, p. 112 - 113 2025
• Gynecologic oncology
  File Brittany, Herzog Thomas, Coleman Robert, Tewari Krishnansu, Kapp Daniel, Monk Bradley, Richardson Michael, Francoeur Alex, Tran Nathan, Chan John, Trends in FDA approval of novel therapies in women's cancer: A study of the last 25 years
  200, p. 114 - 115 2025
• Gynecologic oncology
  Salani Ritu, Lindemann Kristina, Kurtz J. Emmanuel, Zhongqiu L.I.N., Nishio Shin, Oaknin Ana, Valabrega Giorgio, Canova Stefania, Cáceres M. Valeria, Lee Jung-Yun, Harter Philipp, Gilbert Lucy, Sadozye Azmat, Van Gorp Toon, Boere Ingrid, Marth Christian, Duska Linda, Madry Radoslaw, Zagouri Flora, do Rêgo Barros Lilian Arruda, Monk Bradley, Li Xin Tong, Bogusz Agata, Toker Sarper, Mirza Mansoor, TroFuse-020/GOG-3101/ENGOT-cx20: A phase III, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy versus treatment of physician's choice as second-line treatment for recurrent or metastatic cervical c
  200, p. 121 - 122 2025
• Gynecologic oncology
  Richardson Michael, Kapp Daniel, Chan John, Herzog Thomas, Coleman Robert, Monk Bradley, Gynecologic cancers in tumor-agnostic trials: Keys to regulatory approval
  200, p. 74 2025
• Gynecologic oncology
  Bujnak Alyssa, Hamilton Alina, Hari Anjali, Hoadley Katherine, Lankes Heather, Monk Bradley, Birrer Michael, Sill Michael, Ramirez Nilsa, Szot Christopher, Wei Lei, Tewari Krishnansu, Huang Helen, Landrum Lisa, Liu Hongwei, Penson Richard, Ramondetta Lois, Michael Helen, Oaknin Ana, Reid Thomas, Leitao Mario, Copeland Larry, Jones Corbin, Reeves Catherine, Predictive biomarkers for chemotherapy plus bevacizumab in recurrent/metastatic cervical cancer: The NRG Oncology/GOG-0240 National Institutes of Health Cancer Moonshot
  200, p. 352 - 353 2025
• Gynecologic oncology
  Lee Jung-Yun, Oaknin Ana, Lee Yeh Chen, Lorusso Domenica, Kim Kidong, Gilbert Lucy, Gao Bo, Tan David, Monk Bradley, Oza Amit, Miller Rowan, O'Malley David, Pothuri Bhavana, Lu Lin, Berman Craig, Borgman Anne, Naumann Wendel, Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: Results from the dose-optimization stage of the REFRαME-O1 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase II/III study
  200, p. 351 2025
• Annals of oncology
  Mercieca-Bebber R., Holschneider C., Buck M., Brooks S., Lea J., Stuckey A., Lad T.E., Spirtos N., Boyd L., Fyles A., Monk B., Barnes E., Stockler M., King M.T., Mileshkin L., Moore K., Diamante K., Lee Y.C., Narayan K., Khaw P., 1172P The relationship between patient-reported outcomes and clinician-rated toxicity in participants with locally advanced cervix cancer in the OUTBACK trial
  36, p. S772 - S773 2025
• Annals of oncology
  Lorusso D., Muller C.Y., Monk B.J., Park J-Y., Colombo N., Van Gorp T., Kim J-W., Gladieff L., Olawaiye A., Madrid L. Fariñas, Bertrán A. Santaballa, Felberbaum R., Bodnar L., Pai S., Thaker P.H., Pashova H.I., Yadav B.K., Mallen A., 1239eTiP BELLA: A phase II study of relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer
  36, p. S748 - S748 2025
• Annals of oncology
  Monk B.J., Lorusso D., Van Nieuwenhuysen E., Tromp J., Zikan M., O'Cearbhaill R.E., Banerjee S., Collins D.C., Jackson A.L., Madsen K., Gennigens C., Baurain J-F., Ottevanger P.B., Ghamande S., Salutari V., Reyners A., Conte U., Windfeld K., Hansen H., Vergote I., 1166P Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/GOG-3024/ENGOT-cx8 study
  36, p. S769 - S770 2025
• Gynecologic oncology
  Chase Dana, Monk Bradley, Small William, Huang Helen, Deng Wei, Rodgers William, Mayadev Jyoti, Leath Charles, Kim Beob-Jong, Albuquerque Kevin, Kim Dae-Yeon, Cho Chi-Heum, Gil Karen, Fabian Denise, Ryu Sang Young, Kim Jae-Weon, No Jae Hong, Holman Laura, Stuckey Ashley, Smick Alexandra, Wenzel Lari, Patient-reported outcomes on a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate-risk, stage I/IIA cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy (NCT#01101451)
  200, p. 4 - 5 2025
• Gynecologic oncology
  Simpkins Fiona, Leary Alexandra, Willmott Lyndsay, Monk Bradley, Frenel Jean-Sebastien, Goh Jeffrey, Slomovitz Brian, Lim Peter, Shannon Catherine, Neff Robert, Kim Doris, Li Hailun, Jandial Danielle, Backes Floor, Starks David, Okera Meena, Secord Angeles Alvarez, O'Malley David, Martin Lainie, Ouali Kaissa, Oehler Martin, Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: Outcomes from part 1b of the DENALI study (GOG-3066)
  200, p. 8 - 9 2025
• Gynecologic oncology
  Ryu Sang Young, Albuquerque Kevin, Deng Wei, Koh Wui-Jin, Mayadev Jyoti, Heugel Anne, Kim Beob-Jong, Kim Jae-Weon, Kim Dae-Yeon, Cho Chi-Heum, No Jae Hong, Mannel Robert, Miller Katherine, Fabian Denise, Small William, Rodgers William, Leath Charles, Monk Bradley, Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical carcinoma following radical hysterectomy and lymphadenectomy: Results of NRG oncology/GOG-263
  200, p. 4 2025
• Gynecologic oncology
  Grisham Rachel, Van Nieuwenhuysen Els, Aghajanian Carol, Monk Bradley, Clamp Andrew, D’hondt Veronique, Derio Silvia, Prendergast Emily, Oaknin Ana, Ring Kari, Holloway Robert, Rodrigues Manuel, Chon Hye Sook, Gourley Charlie, Santin Alessandro, Thaker Premal, Gennigens Christine, Newman Gregg, Moore Kathleen, Lustgarten Stephanie, O'Malley David, Salinas Erin, Youssoufian Hagop, Van Gorp Toon, Banerjee Susana, ENCORE: Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer (ENGOT-OV60/GOG-3052/RAMP 201): Dose intensity and subgroup analysis
  200, p. 34 - 35 2025
• Cancer treatment and research communications
  Monk Bradley J., Gordan Lucio N., Patel Manish R., Toker Sarper, Subbiah Vivek, DEVELOPMENT OF ANTI-CANCER MEDICINES IN THE CURRENT ERA, p. 101002 - 101002 2025
• International journal of gynecological cancer
  Podder Vivek, Coleman Robert L., Eskander Ramez, Flint Michelle, Monk Bradley J., Slomovitz Brian M., Checkpoint Inhibitor Rechallenge in Advanced Endometrial Cancer: Revisiting the Immune Landscape Beyond First-Line Therapy, p. 102124 2025
• Journal of clinical oncology
  Konstantinopoulos Panagiotis A, Su Fei, Hinson Patsy, Zuradelli Monica, Wang Craig, Paule Ines, Miller Michelle, Matulonis Ursula A, González-Martín Antonio, Freyer Gilles, Kim Jae Weon, Lee Jung Yun, Wu Xiaohua, Gaba Lydia, Grisham Rachel N, Colombo Nicoletta, Monk Bradley J, Sehouli Jalid, Cruz Felipe, Cibula David, Van Nieuwenhuysen Els, Nyvang Gitte-Bettina, Friedlander Michael, Lorusso Domenica, Leary Alexandra, Malik Rozita, Glasspool Rosalind, Marth Christian, Sufliarsky Jozef, Cortés-Salgado Alfonso, Zamagni Claudio, Marmé Frederik, Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation, p. JCO2500225 2025
• Journal of clinical oncology
  Banerjee Susana N, Monk Bradley J, Van Nieuwenhuysen Els, Aghajanian Carol, D'Hondt Véronique, Prendergast Emily, Oaknin Ana, Ring Kari, Clamp Andrew, Gennigens Christine, Colombo Nicoletta, Holloway Robert W, Rodrigues Manuel, Chon Hye Sook, Gourley Charlie, Santin Alessandro D, Thaker Premal H, Moore Kathleen N, Newman Gregg, Salinas Erin, Youssoufian Hagop, Grisham Rachel N, Lustgarten Stephanie, O'Malley David M, Van Gorp Toon, , Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201, p. JCO2500112 2025
• Gynecologic oncology
  Chan John K., Tewari Krishnansu, McHale Michael T., Monk Bradley J., Herzog Thomas J., Coleman Robert L., Richardson Michael T., Salani Ritu, Francoeur Alex A., Kapp Daniel S., Optimizing therapy for cervical cancers – Translating trial data into clinical decision-making
  199, p. 47 - 50 2025
• Annals of oncology
  Mayadev J, Rey F, Kahán Z, Galaz P, Meléndez Mier G, Wu X, Mandai M, Estevez-Diz M D P, Limaye S, Xin W, Shapira-Frommer R, Stewart R A, Dry H, Broggi M A S, Yuan D Y, Monk B J, Varga S, Ramírez Godinez F J, Leiva M, Cetina-Pérez L D C, Molina Alavez A, Alarcon-Rozas A E, Valdiviezo N, Acevedo C, Figueroa A, Santini A, Vera L, Vázquez Limón J C, Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses 2025
• The Lancet (British edition)
  Olawaiye Alexander B, Artioli Grazia, Gladieff Laurence, O'Malley David M, Kim Jae-Weon, Garbaos Gabriel, Salutari Vanda, Caruso Giuseppe, Nicum Shibani, Bagaméri Andrea, Kesner-Hays Amanda, Bodnar Lubomir, Kang Sokbom, Vergote Ignace, Jubb Adrian M, Pashova Hristina I, Pai Sachin G, Tudor Iulia Cristina, Hopp Elizabeth, Gilbert Lucy, Mileshkin Linda, Devaux Alix, Lorusso Domenica, Lee Yong Jae, Oaknin Ana, Scaranti Mariana, Kim Byoung-Gie, Clamp Andrew, Colombo Nicoletta, McCollum Michael E, Diakos Connie, Scandurra Giuseppa, Leiser Aliza L, Balázs Boglárka, Monk Bradley J, De La Cueva Helena, McClung Emily, Kaczmarek Emilie, Slomovitz Brian, de Carvalho Calabrich Aknar Freire, Churruca Cristina, Cassani Chiara, You Benoit, Van Gorp Toon, Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial 2025
• International journal of gynecological cancer
  Lightfoot Michelle DS, Lutz Kathleen, Rubinstein Maria M., Monk Bradley J., Eskander Ramez N., Moore Kathleen N., Herzog Thomas J., Pothuri Bhavana, Oral Mucositis Associated with Antibody-Drug Conjugates in Gynecologic Oncology: Strategies for Prevention and Treatment, p. 101997 2025
• Journal of clinical oncology
  Bujnak Alyssa, Birrer Michael J., Hamilton Alina, Sill Michael, Monk Bradley J., Hari Anjali, Penson Richard T., Lankes Heather A., Hoadley Katherine A., Liu Hongwei, Szot Christopher, Ramondetta Lois M., Oaknin Ana, Leitao Mario Mendes, Copeland Larry J., Ramirez Nilsa C., Wei Lei, Tewari Krishnansu Sujata, miRNA(s) expression as predictive biomarkers in recurrent/metastatic cervical cancer: The NRG Oncology/GOG-0240 NIH Cancer Moonshot
  43:16_suppl, p. 5523 - 5523 2025
• International journal of gynecological cancer
  Secord Angeles Alvarez, Alvarez Ronald D., Small Michelle N., Randall Leslie M., Mannel Robert S., Mutch David, Coleman Robert L., Herzog Thomas J., Monk Bradley J., Moore Kathleen N., Copeland Larry J., Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: The GOG Foundation, Inc.’s Scholar Career Development Award and New Investigator Program, p. 101982 2025
• Journal of clinical oncology
  Shahin Mark S., Moore Richard G., Hietanen Sakari, O’Cearbhaill Roisin E., Mangili Giorgia, Berton Dominique, Rubio-Pérez Maria Jesús, Burger Robert Allen, Braicu Elena Ioana, Monk Bradley J., Shtessel Luda, Cloven Noelle, Aaquist Haslund Charlotte, Herzog Thomas J, Lim Jonathan, Gonzalez Martin Antonio, McCormick Colleen C., Barretina-Ginesta Maria-Pilar, O’Malley David M., Honhon Brigitte, Impact of disease progression on health-related quality of life (HRQOL): Updated results from the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line (1L) maintenance therapy in patients with newly diagnosed advanced ovarian cancer (aOC)
  43:16_suppl, p. 5551 - 5551 2025
• Journal of clinical oncology
  Mayadev Jyoti, Vázquez Limón Juan Carlos, RamIrez Godinez Francisco Javier, Leiva Manuel, Alarcon-Rozas Ashley Efrain, Cetina Lucely Del Carmen, Varga Szilvia, Molina Alavez Alejandro, Valdivieso Natalia, Wu Xiaohua, Limaye Sewanti Atul, Mandai Masaki, Shapira-Frommer Ronnie, Estevez-Diz Maria Del Pilar, Xin Wenjing, Broggi Maria, Stewart Ross, Monk Bradley J., Yuan Daniel Y., Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses
  43:16_suppl, p. 5502 - 5502 2025
• Journal of clinical oncology
  Salani Ritu, Lin Zhongqiu, Lindemann Kristina, Mirza Mansoor Raza, Nishio Shin, Cáceres Valeria, Oaknin Ana, Kurtz Jean Emmanuel, Valabrega Giorgio, Harter Philipp, Van Gorp Toon, Gilbert Lucy, Sadozye Azmat, De Rêgo Barros Lilian Arruda, Boere Ingrid A., Monk Bradley J., Marth Christian, Duska Linda R., Li Xin Tong, Tekin Cumhur, , TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of physician’s choice as second-line treatment for recurrent or metastatic cervical cancer
  43:16_suppl 2025
• Journal of clinical oncology
  Mercieca-Bebber Rebecca, Lee Yeh Chen, Barnes Elizabeth H., Moore Kathleen N., Fyles Anthony, Narayan Kailash, Khaw Pearly, Buck Martin, Brooks Susan, Holschneider Christine, Lea Jayanthi Sivasothy, Stuckey Ashley, Lad Thomas E., Spirtos Nicola M., Stockler Martin R., Boyd Leslie R., Small William, Monk Bradley J., Mileshkin Linda R., King Madeleine T., Patient-reported outcomes (PROs) in locally advanced cervical cancer (LACC): Insights from the OUTBACK trial
  43:16_suppl, p. 5503 - 5503 2025
• ESMO open
  Oaknin A., Fujiwara K., Kristeleit R., Monk B.J., Schenker M., Prendergast E., Salutari V., Littell R., Martinez-Garcia J., Yeku O., Ueland F., Lee J-Y., De Vivo R., Dean A., Diaz J., Bese T., Jewell A., Van Gorp T., Maloney L., 75MO Efficacy and safety of rucaparib maintenance treatment in patients from ATHENA-MONO/GOG-3020/ENGOT-ov45 with newly diagnosed advanced ovarian cancer not associated with homologous recombination deficiency
  10 2025
• ESMO open
  Okines A., Oh D-Y., Curigliano G., Mizuno N., Rorive A., Hamilton E.P., Soliman H., Takahashi S., Bekaii-Saab T., Monk B.J., Nakamura Y., Nguyen D., O'Malley D., Reck M., Tan Q., Yu E., Drees A., Ramos J.D., Stinchcombe T., Pohlmann P.R., 304MO Tucatinib and trastuzumab for previously treated HER2-mut MBC: Final analysis of a phase II basket study (SGNTUC-019)
  10, p. 104876 2025
• International journal of gynecological cancer
  Podder Vivek, Cobb Lauren Patterson, Grisham Rachel N., Coleman Robert L., Monk Bradley J., Herzog Thomas, Gershenson David M., Slomovitz Brian M., Repurposing FDA-Approved Cancer Therapies: Exploring Endocrine and Targeted Pathways in Low-Grade Serous Ovarian Cancer Treatment, p. 101938 2025
• Cancer treatment reviews
  Monk Bradley J., Sehouli Jalid, Lorusso Domenica, Fujiwara Keiichi, Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review, p. 102945 2025
• Gynecologic oncology
  Matulonis Ursula A., Mahner Sven, Berton Dominique, Berek Jonathan S., Redondo Andrés, Herrstedt Jørn, Oza Amit, Lindahl Gabriel, Haslund Charlotte A., Marmé Frederik, Tinker Anna V., Ledermann Jonathan A., Benigno Benedict, Mirza Mansoor R., González-Martín Antonio, Bécourt Stéphanie, Bains Manjinder, Colombo Nicoletta, Malinowska Izabela A., Liu Wenlei, Monk Bradley J., ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
  195, p. 192 2025
• Gynecologic oncology
  Leath, 3rd Charles A, Deng Wei, Mell Loren K, Santos-Reyes Luis Javier, Richardson Debra L, Walker Joan L, Holman Laura L, Lea Jayanthi S, Amarnath Sudha R, Arend Rebecca C, Chon Hye Sook, Mayadev Jyoti, Jegadeesh Naresh, DiSilvestro Paul, Chino Junzo P, Ghamande Sharad A, Gao Lei, Albuquerque Kevin, Quick Allison M, Donnelly Eric, Feddock Jonathan M, Lowenstein Jessica, Kunos Charles M, MacKay Helen, Aghajanian Carol, Monk Bradley J, Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial
  195, p. 122 - 133 2025
• Gynecologic oncology
  Carter Jeanne, Huang Helen Q, Monk Bradley J, Kim Yong-Beom, Kim Moon-Hong, Stuckey Ashley, Vicus Danielle L, Holman Laura L, Fleury Aimee C, Pearson J Matthew, Thawani Nitika, Shahin Mark, Lea Jayanthi, Robertson Sharon E, Warshal David, Backes Floor J, Feltmate Colleen, Wilkinson-Ryan Ivy, Covens Allan, Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278)
  195, p. 50 2025
• Gynecologic oncology
  Covens Allan, DiSilvestro Paul, Monk Bradley J, Kim Yong-Beom, Kim Moon-Hong, Huang Helen Q, Fleury Almee, Pearson J Matthew, Thawani Nitika, Vicus Danielle, Holman Laura L, Shahin Mark S, Lea Jayanthi S, Robertson Sharon E, Feltmate Colleen, Dewdney Summer, Leitao Mario M, Wilkinson-Ryan Ivy, Warshal David, Backes Floor, Elsayed Ahmed G, Carter Jeanne, Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278)
  195, p. 59 2025
• International journal of gynecological cancer
  Leitao Mario M., Randall Leslie M., Lim Peter C., Bixel Kristin L., Chase Dana Meredith, Quick Allison, McCormick Colleen, Black Destin, Eskander Ramez N., Gotlieb Walter H., LoCoco Salvatore, Martino Martin A., Walker Joan L., Copeland Larry J., Monk Bradley J., ROCC/GOG-3043: A randomized controlled trial of robotic versus open surgery for early-stage cervical cancer, p. 101760 2025
• International journal of gynecological cancer
  Salani Ritu, Lindemann Kristina, Lin Zhongqiu, Valabrega Giorgio, Nishio Shin, Oaknin Ana, Kurtz Jean-Emmanuel, Cáceres M. Valeria, Harter Philipp, Van Gorp Toon, Gilbert Lucy, Sadozye Azmat H., Do Rêgo Barros Lilian Arruda, Boere Ingrid, Marth Christian, Mirza Mansoor Raza, Monk Bradley J., Li Xin Tong, Tekin Cumhur, Duska Linda, TroFuse-020/GOG-3101/ENGOT-Cx20: A Phase 3, Randomised, Active-Controlled, Open-Label, Multicentre Study Comparing Sacituzumab Tirumotecan Monotherapy Vs Treatment Of Physician’s Choice As Second-Line Treatment For Recurrent Or Metastatic Cervical Cancer
  35:2, p. 100497 2025
• International journal of gynecological cancer
  Ghamande Sharad, Prendergast Emily, Miller Rowan E., Solovyeva Ekaterina, Del Mar Gordon Santiago Maria, Kim Yong-Man, Littell Ramey, Fujiwara Keiichi, Anttila Maarit, Connor Christy, Craib Marcia, Monk Bradley J., Kristeleit Rebecca S., Turna Hande, Ruiz Nuria, Bessette Paul, Van Le Linda, Westin Shannon N., Zvaríková Mária, Eskander Ramez N., ATHENA-MONO Post-Progression Survival Data Update In Patients With Newly Diagnosed Advanced Ovarian Cancer
  35:2, p. 100319 2025
• International journal of gynecological cancer
  Lokich Elizabeth, Jørgensen Trine Lembrecht, Black Destin, Cibula David, Gilbert Lucy, Savarese Antonella, Powell Matthew A., Herbertson Rebecca, Gill Sarah E., Monk Bradley J., Nevadunsky Nicole, Cloven Noelle, Podzielinski Iwona, Myers Tashanna, Dabrowski Christine, Ring Kari L., Stevens Shadi, Willmott Lyndsay, Mirza Mansoor Raza, Time Course Of Adverse Events In Primary Advanced Or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy In The ENGOT-EN-6-NSGO/GOG-3031/RUBY Trial
  35:2, p. 101722 2025
• European journal of cancer (1990)
  Vergote Ignace, Thaker Premal H., Van Gorp Toon, Laenen Annouschka, Scambia Giovanni, Cibula David, Colombo Nicoletta, Lea Jayanthi, Monk Bradley J., Gonzalez-Martin Antonio, Korach Jacob, Sehouli Jalid, Heinzelmann-Schwarz Viola, Berger Regina, Buscema Joseph, Lau Susie, Mądry Radoslaw, Denys Hannelore, Pepin Jessica Thomes, Salutari Vanda, Bagaméri Andrea, Ardizzoia Antonio, Copeland Larry J., Henry Stéphanie, Cecere Sabrina Chiara, Hruda Martin, Iglesias David A., Manso Luis, Shai Ayelet, O’Malley David M., Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study, p. 115306 2025
• International journal of gynecological cancer
  Lorusso Domenica, Pothuri Bhavana, Monk Bradley J., Barretina-Ginesta Maria-Pilar, Vergote Ignace, O’malley David M., Haslund Charlotte A., Heitz Florian, O’cearbhaill Roisin E., Abadie-Lacourtoisie Sophie, Backes Floor J., Chase Dana M., Amit Amnon, Moore Kathleen N., Malinowska Izabela A., Graybill Whitney S., Herzog Thomas J., Golembesky Amanda K., Rubio Pérez Maria-Jesús, González-Martín Antonio, Updated Patient-Reported Outcomes In The PRIMA/ENGOT-OV26/GOG-3012 Trial Of Niraparib First-Line Maintenance Therapy In Patients With Newly Diagnosed Advanced Ovarian Cancer
  35:2, p. 100093 2025
• Gynecologic oncology
  Bogani Giorgio, Lorusso Domenica, Moore Kathleen N., Ray-Coquard Isabelle, Matulonis Ursula A., Ledermann Jonathan A., González-Martín Antonio, Kurtz Jean-Emmanuel, Raspagliesi Francesco, Pujade-Lauraine Eric, Scambia Giovanni, Caruso Giuseppe, Colombo Nicoletta, Monk Bradley J., Incorporating immune checkpoint inhibitors in epithelial ovarian cancer
  193, p. 30 - 40 2025
• American journal of obstetrics and gynecology
  Levin Gabriel, Coleman Robert, Monk Bradley J, Pothuri Bhavana, Herzog Thomas, Gilbert Lucy, Bernard Laurance, Zeng Xing, Scalia Peter, Slomovitz Brian, Racial and ethnic enrollment disparities in clinical trials leading to FDA approvals for gynecologic malignancies, p. - 2025
• Nature medicine
  Okines Alicia F C, Curigliano Giuseppe, Mizuno Nobumasa, Takahashi Shunji, Oh Do-Youn, Rorive Andree, Soliman Hatem, Bekaii-Saab Tanios, Fox Jenny R, Burkard Mark E, Chung Ki Y, Debruyne Philip R, Monk Bradley J, Gambardella Valentina, Gil-Martin Marta, Hamilton Erika P, Olawaiye Alexander B, Nakamura Yoshiaki, Nguyen Danny, O'Malley David M, Sunakawa Yu, Pothuri Bhavana, Reck Martin, Sudo Kazuki, Van Marcke Cedric, Bieda Mark, Yu Evan Y, Ramos Jorge, Tan Sherry, Stinchcombe Thomas E, Pohlmann Paula R, Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial 2025
• European journal of cancer (1990)
  Oaknin Ana, Gotovkin Evgeniy, Monk Bradley J, Lorusso Domenica, Damian Fernanda, Chang Chih-Long, Pikiel Joanna, Goh Jeffrey C, Hasegawa Kosei, Mora Paulo, Srivastav Ratnesh, Colombo Nicoletta, Fury Matthew G, Tewari Krishnansu S, Polastro Laura, Alia Eva Maria Guerra, Makarova Yulia, Rischin Danny, Rubio Maria Jesús, Perez Javier, Seebach Frank, Yoo Suk Young, Gao Bo, Jamil Shaheda, Lowy Israel, Takahashi Shunji, Ramone Daniella, Maćkowiak-Matejczyk Beata, Mathias Melissa, Samouëlian Vanessa, de Melo Andreia Cristina, Kim Hee Seung, Kim Yong Man, Lisyanskaya Alla S, Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial
  216, p. 115146 2025
• Nature reviews. Clinical oncology
  Francoeur Alex A, Monk Bradley J, Tewari Krishnansu S, Treatment advances across the cervical cancer spectrum 2025
• Therapeutic advances in medical oncology
  Powell Matthew A, Novák Zoltán, Black Destin, Gilbert Lucy, Sharma Sudarshan, Stuckey Ashley, Boere Ingrid, Gold Michael A, Segev Yakir, Pothuri Bhavana, Monk Bradley J, Shahin Mark S, Grimshaw Matthew, Stevens Shadi, Lai Dominic W, McCourt Carolyn, Mirza Mansoor Raza, Buscema Joseph, Coleman Robert L, Gennigens Christine, Sebastianelli Alexandra, Gill Sarah E, Valabrega Giorgio, Landrum Lisa M, Gropp-Meier Martina, Slomovitz Brian M, Ring Kari L, Herzog Thomas J, Balas Morad Marco, Bjørge Line, Willmott Lyndsay, A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel
  17, p. 17588359251342241 2025
• Journal of gynecologic oncology
  Kim Yong-Man, Tewari Krishnansu S., Hasegawa Kosei, Dubot Coraline, Cáceres M. Valeria, Lorusso Domenica, Kim Se Ik, Lee Jeong-Won, Liou Wen-Shiung, Li Kan, Nishio Shin, Tekin Cumhur, Colombo Nicoletta, Monk Bradley J., Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis
  36 2025
• Mirza Mansoor R, Chase Dana M, Slomovitz Brian M, Gilbert Lucy, Coleman Robert L, Powell Matthew A, Christensen René de Pont, Novák Zoltán, Black Destin, Sharma Sudarshan, Valabrega Giorgio, Landrum Lisa M, Hanker Lars C, Stuckey Ashley, Boere Ingrid, Gold Michael A, Auranen Annika, Raspagliesi Francesco, Pothuri Bhavana, Cibula David, McCourt Carolyn, Shahin Mark S, Gill Sarah E, Monk Bradley J, Stevens Shadi, Copeland Larry J, Tian Min, He Zangdong, Buscema Joseph, Herzog Thomas J, Zografos Eleftherios, A Plain Language Summary of “Dostarlimab for primary advanced or recurrent endometrial cancer” 2025
• Journal of comparative effectiveness research
  Graybill Whitney S, Heitz Florian, Willmott Lyndsay J, Bruchim Ilan, Zhuo Ying, Pothuri Bhavana, Anttila Maarit, O'Malley David M, Lorusso Domenica, Estévez-García Purificación, Monk Bradley J, Denys Hannelore, Knudsen Anja, Tinker Anna V, Haggerty Ashley F, Fabbro Michel, Chan John K, Vergote Ignace, Sánchez Luis Manso, Provencher Diane, Barretina-Ginesta Maria Pilar, Hartman John, Booth Donna V, González-Martín Antonio, Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
  14:1, p. e240133 2025
• J Comp Eff Res
  Graybill Whitney S, Vergote Ignace, Pothuri Bhavana, Anttila Maarit, O'Malley David M, Lorusso Domenica, Haggerty Ashley F, Fabbro Michel, Chan John K, Heitz Florian, Willmott Lyndsay J, Bruchim Ilan, Zhuo Ying, Sánchez Luis Manso, Provencher Diane, Estévez-García Purificación, Monk Bradley J, Denys Hannelore, Knudsen Anja, Tinker Anna V, Barretina-Ginesta Maria Pilar, Hartman John, Booth Donna V, González-Martín Antonio, Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
  14:1, p. e240133 2025
• Annals of oncology
  González-Martín A, Malinowska I A, Monk B J, Reply to Letter to the Editor 'Long-term outcomes in the PRIMA trial: a closer look at PFS and OS' by Wu et al 2024
• Cancer research communications
  Zhang Hailei, Rutkowska Anna, González-Martín Antonio, Mirza Mansoor R, Monk Bradley J, Vergote Ignace, Graybill Whitney A Spannuth, Goessel Carsten, Barbash Olena, Bergamini Giovanna, Pothuri Bhavana, Feng Bin, Potential synergistic effect between niraparib and statins in ovarian cancer clinical trials 2024
• Cancer Res Commun
  Zhang Hailei, Monk Bradley J, Rutkowska Anna, González-Martín Antonio, Mirza Mansoor R, Vergote Ignace, Pothuri Bhavana, Graybill Whitney A. Spannuth, Goessel Carsten, Barbash Olena, Bergamini Giovanna, Feng Bin, Potential synergistic effect between niraparib and statins in ovarian cancer clinical trials 2024
• Oncology and therapy
  Monk Bradley J., Tekin Cumhur, Keefe Steve, Monberg Matthew, Muston Dominic, Boer Jennifer, van Mens Sophie, Hale Oliver, van Hees Frank, Swami Shilpi, Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States 2024
• Gynecologic oncology
  Grisham Rachel, Lustgarten Stephanie, Thaker Premal, Oza Amit, Colombo Nicoletta, Denis Louis, O'Malley David, Banerjee Susana, Monk Bradley, Nieuwenhuysen Els, Moore Kathleen, Fabbro Michel, Oaknin Ana, A phase III, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of therapy among patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-OV81/NCRI/RAMP 301
  190, p. S282 - S283 2024
• Gynecologic oncology
  Banerjee Susana, Moore Kathleen, Clamp Andrew, Ray-Coquard Isabelle, Chon Hye Sook, Salinas Erin, Monk Bradley, Rose Peter, O'Malley David, Oaknin Ana, Holloway Robert, Gennigens Christine, Moroney John, Van Gorp Toon, Kalbacher Elsa, Newman Gregg, Van Nieuwenhuysen Els, Colombo Nicoletta, Wojtynek Nicholas, Lustgarten Stephanie, Grisham Rachel, Santin Alessandro, Ring Kari, Thaker Premal, Prendergast Emily, Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: A subgroup analysis of ENGOT-OV60/GOG-3052/RAMP 201 Part A
  190, p. S55 - S56 2024
• Gynecologic oncology
  Moore Kathleen, Williams Dennis, Musa Fernanda, Nathenson Michael, Sauer Amy, Jolliffe Darren, Rosenberg Marisa, Norry Elliot, Monk Bradley, Ray-Coquard Isabelle, Oaknin Ana, Coleman Robert, Rose Peter, Herzog Thomas, O'Malley David, Lheureux Stephanie, Morris Robert, Starks David, Lanneau Grainger, GOG-3084: A phase II trial of ADP-A2M4CD8 TCR-T cell therapy, alone or in combination with nivolumab, among patients with recurrent ovarian cancers
  190, p. S281 - S282 2024
• Gynecologic oncology
  Graybill Whitney, Haggerty Ashley, Fabbro Michel, Chan John, Heitz Florian, Willmott Lyndsay, Bruchim Ilan, Zhuo Ying, Estévez-García Purificación, Monk Bradley, Denys Hannelore, Vergote Ignace, Pothuri Bhavana, Anttila Maarit, O'Malley David, Lorusso Domenica, Knudsen Anja, Tinker Anna, Sánchez Luis Manso, Provencher Diane, Barretina-Ginesta M. Pilar, Hartman John, Booth Donna, González-Martín Antonio, Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
  190, p. S274 - S275 2024
• Gynecologic oncology
  Pothuri Bhavana, Oaknin Ana, Monk Bradley, Graybill Whitney, Sánchez Ana Beatriz, Levy Tally, York Whitney, Malinowska Izabela, González-Martín Antonio, Denys Hannelore, McCormick Colleen, Baurain Jean-François, Tinker Anna, O'Cearbhaill Roisin, de La Motte Rouge Thibault, Hietanen Sakari, Moore Richard, Knudsen Anja, Heitz Florian, Valabrega Giorgio, Examining health-related quality of life outcomes among older patients with advanced ovarian cancer treated with niraparib first-line maintenance therapy in context with efficacy and safety findings: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
  190, p. S295 - S296 2024
• Gynecologic oncology
  Hunsberger Kyra, Tewari Krishnansu, Randall Leslie, Chase Dana, Monk Bradley, Standard of care treatment for stage IVB cervical cancer: A systematic review and meta-analysis
  190, p. S421 - S421 2024
• Gynecologic oncology
  Kristeleit Rebecca, O'Malley David, Lim Myong Cheol, Miller Rowan, Coleman Robert, Monk Bradley, Herzog Thomas, Wilson Michelle, De Vivo Rocco, Oaknin Ana, Chudecka-Glaz Anita, Oza Amit, Mikheeva Olga, Buscema Joseph, Van Le Linda, Morris Robert, Van Gorp Toon, Moore Kathleen, Zagouri Flora, Shih Danny, Rob Lukáš, Craib Marcia, Connor Christy, Fujiwara Keiichi, Interim post-progression data and updated survival in patients with newly diagnosed advanced ovarian cancer in ATHENA-MONO
  190, p. S10 - S11 2024
• Gynecologic oncology
  Banerjee Susana, Marsolini Diane, Westin Shannon, Roxburgh Patricia, Eskander Ramez, Sardone Megan, Ray-Coquard Isabelle, Moore Kathleen, Berton Dominique, Monk Bradley, Van Nieuwenhuysen Els, O'Malley David, Oaknin Ana, Barlin Joyce, Anderson Charles, Redondo Andrés, Brubaker Lindsay, Ang Joo Ern, Cloven Noelle, Baurain Jean-François, A phase Ib, multicenter, open-label study of NXP800, a novel GCN2 kinase activator, among patients with platinum-resistant, ARID1A-mutated ovarian cancer (ENGOT-GYN5/NCRI/NXP800-101; GOG-3087)
  190, p. S302 - S302 2024
• Annals of oncology
  Lorusso D, Colombo N, Dubot C, Cáceres M V, Hasegawa K, Gümüş M, Shapira-Frommer R, Salman P, Yañez E, Olivera M, Toker S, Castonguay V, Arkhipov A, Li K, Samouëlian V, Tekin C, Tewari K S, Monk B J, Pembrolizumab Plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study 2024
• International journal of gynecological cancer
  Barlin Joyce, Eshed Helen, Black Destin, Cottrill Hope, Hand Lauren, O’Malley David, Chuang Linus, Chisamore Michael, Durbin Joan, Zheng Pan, Lim Peter, Pepin Jessica Thomes, Hopp Elizabeth, Cloven Noelle, Monk Bradley, Liu Yang, Shpyro Svetlana, LB010/#1590  A phase 2 randomized dose optimization trial of gotistobart, a PH-sensitive anti-CTLA-4, in combination with pembrolizumab in platinum-resistant ovarian cancer (PROC, preserve-004/GOG-3081; NCT05446298)
  34, p. A6 - A8 2024
• International journal of gynecological cancer
  Lorusso Domenica, Van Gorp Toon, Zagouri Flora, Bodnar Lubomir, Collins Dearbhaile, Korach Jacob, Marth Christian, Kroep Judith, Zhu Jianqing, Hasegawa Kosei, Samouëlian Vanessa, Lee Jung-Yun, Casarotto Fernanda, Antill Yoland, Chase Dana, Shahin Mark, Orlowski Robert, Woodhouse Kristina, Cui Yi, Willmott Lyndsay, Monk Bradley, TP003/#1538  Phase 3 ENGOT-en23/GOG-3095/MK-2870–005 study: sacituzumab tirumotecan (Sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who received prior chemotherapy and immunotherapy
  34, p. A348 - A348 2024
• International journal of gynecological cancer
  Grisham Rachel, Monk Bradley, O’Malley David, Van Nieuwenhuysen Els, Moore Kathleen, Fabbro Michel, Colombo Nicoletta, Oaknin Ana, Thaker Premal, Oza Amit, Lustgarten Stephanie, Youssoufian Hagop, Banerjee Susana, PR029/#943  A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of therapy in patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-ov81/NCRI/RAMP 301
  34, p. A53 - A54 2024
• International journal of gynecological cancer
  Bixel Kristin, Baiocchi Glauco, Black Destin, Lococo Salvatore, Eskander Ramez, Gotlieb Walter, Lee Sun Joo, Randall Leslie, Martino Martin, Mccormick Colleen, Monk Bradley, Quick Allison, Walker Joan, Leitao Mario, Chase Dana, TP001/#1584  GOG-3043 (nct04831580): a randomized non-inferiority trial of robotic versus open surgery for early stage cervical cancer (ROCC)
  34, p. A347 - A347 2024
• International journal of gynecological cancer
  Oaknin Ana, Lorusso Domenica, Lee Jung-Yun, Pietzner Klaus, Auranen Annika, Cibula David, Lee Yeh Chen, Schilder Russell, Gao Bo, Salutari Vanda, Tan David, Oza Amit, Miller Rowan, Pothuri Bhavana, Tasca Giulia, O’Malley David, Monk Bradley, Wendel Naumann R., Lu Lin, Berman Craig, Borgman Anne, TP010/#1537  Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: the reframe-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study
  34, p. A351 - A351 2024
• International journal of gynecological cancer
  Banerjee Susana, Youssoufian Hagop, Kalbacher Elsa, Van Gorp Toon, Lustgarten Stephanie, Van Nieuwenhuysen Els, Grisham Rachel, Aghajanian Carol, Santin Alessandro, Ring Kari, Colombo Nicoletta, Chon Hye Sook, Thaker Premal, Prendergast Emily, Moore Kathleen, Cortés-Salgado Alfonso, Clamp Andrew, O’malley David, Monk Bradley, Fabbro Michel, LB007/#1548  Efficacy and safety of avutometinib ± defactinib in recurrent low grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201
  34, p. A13 - A13 2024
• European journal of cancer (1990)
  Nakamura Y., Monk B.J., Bekaii-Saab T., Hayashi H., Mizuno N., Nguyen D., Hamilton E., Okines A., O’Malley D.M., Pohlmann P.R., Reck M., Pothuri B., Sudo K., Sunakawa Y., Takahashi S., Yu E.Y., Drees A., Tan S., Stinchcombe T.E., 3 Oral: Tucatinib and Trastuzumab for Patients With Previously Treated, HER2- Altered Solid Tumors (SGNTUC-019): A Phase 2 Basket Study
  211, p. 114532 2024
• Annals of oncology
  Monk B.J., Vergote I., O’Cearbhaill R.E., González-Martín A., Graybill W., Mirza M.R., McCormick C.C., Lorusso D., Heitz F., Moore R.G., Freyer G., Vulsteke C., O’Malley D.M., Redondo A., Shahin M.S., Pisano C., Barretina-Ginesta M.P., Pothuri B., Bradley W.H., Haslund C.A., Chase D.M., Gaba L., Holman L.L., Pérez M. J. Rubio, DiSilvestro P., Shtessel L., Herzog T.J., Bruchim I., Compton N., Malinowska I.A., Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial 2024
• International journal of gynecological cancer
  Vergote Ignace, Colombo Nicoletta, Korach Jacob, Barlin Joyce, Papadimitriou Christos A, van Gorp Toon, Richardson Debra, Li Kai, Kalyanapu Pratheek, Slomovitz Brian, Coleman Robert L, Mirza Mansoor Raza, Valabrega Giorgio, Monk Bradley J, Herzog Thomas, Perez Fidalgo Alejandro, Cibula David, Pothuri Bhavana, Sehouli Jalid, McCarthy Michael, Antill Yoland, ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: ratio
  34:8, p. 1283 2024
• Gynecologic oncology
  Pothuri Bhavana, Churruca Cristina, Burger Robert A., Gaba Lydia, Van Le Linda, Guerra Eva, Bender David, Korach Jacob, Cloven Noelle, Peen Ulla, Follana Philippe, DiSilvestro Paul, Baurain Jean-François, Jardon Kris, Pisano Carmela, Antonova Jenya, Mäenpää Johanna, Gupta Divya, Bacqué Emeline, Li Yong, Compton Natalie, Heitz Florian, Monk Bradley J., González-Martín Antonio, Han Sileny, Chase Dana M., Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
  184, p. 168 - 177 2024
• Chan John, Monk Bradley, McNally Leah, Richardson Michael, Tian Chunqiao, Kesterson Joshua, Lin Ken, Darcy Kathleen, Kapp Daniel, Landrum Lisa, Copeland Larry, Phippen Neil, Berry Laurel, Bell Jeffery, Walker Joan, Wenham Robert, Spirtos Nick, Tewari Krishnansu, Shahin Mark, Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study 2024
• Gynecologic oncology reports
  Rimel Bobbie J., Wang Travis, Chase Dana M., Perhanidis Jessica, Ghazarian Armen A., Du Ella Xiaoyan, Monk Bradley J., Salani Ritu, Song Jinlin, Golembesky Amanda K., Hurteau Jean A., Kalilani Linda, Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance set, p. 101332 2024
• Gynecologic oncology
  Valabrega Giorgio, Graybill Whitney S, Pothuri Bhavana, Oaknin Ana, Tinker Anna V, Sánchez Ana Beatriz, McCormick Colleen, Baurain Jean-François, Moore Richard G, Denys Hannelore, O'Cearbhaill Roisin E, Hietanen Sakari, Knudsen Anja Ør, González-Martín Antonio, de La Motte Rouge Thibault, Heitz Florian, Levy Tally, York Whitney, Gupta Divya, Monk Bradley J, Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial 2024
• Gynecologic oncology
  Chase Dana M., Romeo Marin Margarita, Backes Floor, Han Sileny, Graybill Whitney, Mirza Mansoor Raza, Pothuri Bhavana, Mangili Giorgia, O'Malley David M., Berton Dominique, Willmott Lyndsay, Baumann Klaus, Coleman Robert L., Safra Tamar, Heinzelmann-Schwarz Viola, Lorusso Domenica, Karl Florian M., Woodward Tatia, Monk Bradley J., Gonzalez-Martin Antonio, , Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial
  166:3, p. 494 - 502 2022
• Critical Reviews in Oncology/Hematology
  Monk Bradley J., Dalton Heather, Farley John H., Chase Dana M., Benjamin Ivor, Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer
  86:2, p. 161 - 175 2013
• European Journal of Gynaecological Oncology
  Jordan S. M., Chase D. M., Watanabe T., Osann K., Monk Bradley J., Rutgers J. K., High pathologic misdiagnosis of cervical adenocarcinoma in situ
  34:5, p. 446 - 449 2013